Evidence-Based Diabetes Management | Journals | The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Among insulin-treated, CGM-naive adults, CGM initiation in primary care produced larger HbA1c reductions at 12 months and ...

Eligibility estimates contract from ~13.3 million with obesity/overweight to ~3.8 million Bridge-eligible Part D enrollees after excluding diabetes, OSA, MASH, and current GLP‑1 users. Modeled ...

VRBPAC endorsed mRNA-1010 for adults 50-64 and ≥65 years, unanimously concluding benefits outweighed risks, supporting a late-stage regulatory path toward potential first mRNA seasonal influenza ...

Secret-shopper testing showed 91.8% of online sellers issued GLP-1 RA prescriptions and 69.4% shipped medication, often within one day and sometimes within minutes. Intake workflows commonly lacked ...

IDOV-Safe leverages an unusually high extracellular enveloped virion proportion (~60%) to support true intravenous oncolytic virus delivery despite circulating neutralizing proteins. The phase 1 ...

KRAS G12C occurs in ~3%–4% of CRC, translating to a sizable metastatic population with limited options and strong rationale for KRAS G12C inhibition strategies. Dual KRAS–EGFR blockade leverages ...

The rarity of sarcoma complicates clinical trial design and biomarker-driven treatment, explains Alexander Spira, MD, PhD, ...

Reimbursement uncertainty and absent permanent billing codes remain dominant CGT access barriers, exposing limitations of “buy-and-bill” models and necessitating dedicated staffing and early ...

Progression from F3 to cirrhosis occurred in roughly one year, contrasting STELLAR’s 13% over four years and suggesting trials may underrepresent real-world risk. Among compensated cirrhosis, 29.7% ...

From sequencing decisions to economics of care, Adam Kittai, MD, offers a wide-ranging look at top unresolved questions in CLL treatment today. He also explored when a triplet regimen—acalabrutinib, ...

As oncology care becomes increasingly complex with the introduction of targeted therapies, oncology pharmacists are playing a larger role in translating emerging evidence into clinical practice. Kang: ...